Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

s and the potential to generate near-term revenue through product sales or royalties for the approved indications in China while seeking global approval in new indications.

DelMar will continue the business of DelMar Pharmaceuticals (BC) Ltd., headquartered in Vancouver, British Columbia with clinical operations in Menlo Park, CA, as a subsidiary under the leadership of DelMar Pharmaceuticals (BC) Ltd.'s current management team, headed by Chief Executive Officer Jeffrey Bacha . In connection with the Acquisition, DelMar issued to the former shareholders of DelMar Pharmaceuticals (BC) Ltd. the equivalent of 13,070,000 shares of its common stock.  Details of the transaction will be filed on a Form 8-K with the United States Securities and Exchange Commission.

The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be resold absent registration under or exemption from such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933.

About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 S&P Capital IQ (MHFI) announced today ... on MabVax Therapeutics Holdings Inc . ... biotechnology company focused on the development of vaccine and ... treatment of cancer. MabVax has discovered a pipeline of ... responses generated by patients who have been immunized against ...
(Date:2/26/2015)... Feb. 26, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... President and Chief Executive Officer of Regulus, will present ... th Annual Healthcare Conference on Wednesday, March 4, ... held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... IRVINE, Calif. , Feb. 26, 2015 /PRNewswire/ ... of age-defying aesthetic products for skin and hair ... Market Relations as agency of record for investor ... continues to improve our distribution, sales and diversification ... activities to current and prospective shareholders," stated Ali ...
(Date:2/26/2015)... Innovation is more urgent than ever. ... of the world and transforming global markets in ... to health care, disruption is constantly underway. , ... trends shake the foundations of established business models, ... to survive the next wave of mega-change. , ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ... with reovirus are available today on the ... http://www.aacr.org, and on the Oncolytics,website ... scheduled to,be delivered at the AACR Annual ...
... 13 Silence Therapeutics plc,(AIM: SLN) today announces ... development of a range of novel approaches for ... Silence Therapeutics, leading,expertise in the delivery of siRNA ... delivery of siRNA in vivo using its,proprietary AtuPLEX ...
... Today, March 13, 2008 at 11:00 AM ET -, ... reported results for the year and quarter ended,December 31, 2007. ... to $273,000 for the year ended December 31, 2006.,Revenues for ... the same period in 2006., The net loss for ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting 3Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 2Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 3Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 2Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 3Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 4Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 5
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... farm to the insects which blight them mankind has ... species while falling victim to others. In Biological Diversity: ... the subject of biodiversity through the species that humans ... authors selected 18 such organisms and have used them ...
... including several from the Smithsonian Institution, discovered that leaves ... more veins per unit area than leaves ever had ... water available to the leaves, making it possible for ... better plumbing system may also have radically altered water ...
... Techne Corporation,s (NASDAQ: TECH ) consolidated pretax ... increased 9.5% to $45.4 million compared with $41.4 million ... a result of increased sales and foreign exchange transaction ... expenses. For the nine months ended March 31, 2011, ...
Cached Biology News:First rainforests arose when plants solved plumbing problem 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 3Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 5Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 6Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 7
... BacMagic™ DNA Kit provides a positive selection ... recombinant protein expression in insect cells. The ... generating recombinant baculoviruses by eliminating the time-consuming ... is an AcNPV genome with a portion ...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Biology Products: